Search 

CStone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, 5 late-stage candidates are at pivotal trials. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone's vision is to become globally recognized as a leading Chinese biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.

Curon Biopharmaceutical, founded in June 2018, is a biopharma company with facility in Shanghai focusing on developing next generation anti-cancer therapies. It completed a $150 million USD Series A financing led by 6 Dimensions Capital, Boyu Capital, and Temasek. With its internationally experienced senior executive management team, Curon Biopharma currently holds multiple promising novel cancer immuno-therapeutic agents in its pipeline and is committed to bring next generation cancer immunotherapies to patients. Curon strives to accelerate its pipeline assets clinical development, further expand its portfolio through in-licensing and other forms of collaboration with biotech and pharmaceutical companies around the world to bring more effective treatment options to patients.

• EpimAb Biotherapeutics is a biopharmaceutical R&D company based in Shanghai creating a pipeline of novel biologics focused around oncology and other disease areas of high value to patients using its a proprietary, and unique technology called FIT-Ig (Fabs-In-Tandem Immunoglobulin). Company’s pioneer product EMB-01 is a bispecific antibody based on FIT-Ig platform targeting EGFR as well as c-MET, currently is in being investigated for treatment of solid tumors in global Phase I/II clinical trial. EpimAb aims to commercialize its FIT-Ig technology as broadly as possible and maximize the number of programs based on the platform. Further information please visit www.epimab.com
• 岸迈生物科技有限公司是一家总部位于上海的生物制药研发公司。公司基于自主研发的FIT-Ig®双特异性抗体平台技术,聚焦于肿瘤IO领域的创新药品开发。公司的先锋产品EMB-01是一种基于FIT-Ig®平台的双特异性抗体,针对EGFR和c-MET靶点,目前正在进行针对实体瘤的全球I/II期临床试验。岸迈生物的目标是尽可能广泛地将其FIT-Ig®技术商业化,并最大限度地拓展基于该平台的新药开发。更多信息,请访问公司官网www.epimab.com。

Leading healthcare company in china

Engaged in novel protein drug development and commercialization

HEC Pharm is the pharmaceutical subsidiaries of HEC Group. There has been a public company listed in Hong Kong in HEC Pharm, and another company will be listed in Shanghai next year.

HEC Pharm focuses on the development and commercialization of pharmaceuticals for the therapeutics of anti-infectious diseases, metabolism disorders and oncology. We are hunting for the opportunities of co-development and in-license of the candidates with the potential therapeutics in previous fields.

A public pharmaceutical company

Hong Kong Biotechnology Organization is an independent nonprofit organization (Charities exempted from tax under Section 88 of the Inland Revenue Ordinance) with the goal to promote best practice, raise awareness across the biotechnology industry while providing added value benefits to its members, whether they are students, researchers, entrepreneurs, industry bodies, public or private sector representatives.

Founded by pioneering scientists with extensive life science backgrounds and multi-cultural experience in research and development, engineering and business. Hong Kong Biotechnology Organization aims to establish and facilitate a worldwide platform for the Hong Kong biotech industry, promote awareness, encouraging and enabling international collaboration. We also provide informed opinion and technical advice to government bodies, healthcare institutions and the general public.